We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
MaxCyte
Broadened scope for current MCY-M11 Phase I studyScancell
Transformational £15m capital raise closesHutchison China MediTech
Innovative pipeline closer to realising its potentialScancell
Material fund raise means clinical progress in sightMaxCyte
New products, new deals, attractive prospectsFutura Medical
FDA green lights MED3000 for OTC approvalMaxCyte
Apeiron licence broadens the MaxCyte opportunityBerGenBio
AXL-erating towards new opportunitiesFutura Medical
AGM statement confirms MED3000 filings on trackBonesupport
Swings and roundabouts